Impact of ß-lactam therapy among patients with infections caused by extended-spectrum ß-lactamase-producing Enterobacteriaceae

Status

Active, not recruiting

Phases

Phase 4

Study type

Interventional

Source

CRIS

Registry ID

KCT0001895

Enrollment

150

Registered

2016-04-21

Start date

2013-01-11

Completion date

Unknown

Last updated

2019-03-11

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

Drug : (Control group) ertapenem 1g, IV q 24 hours for 10-14 days, (treatment group 1) cefepime 2g, IV q 12 hours for 10-14 days, (treatment group 2) piperacillin/tazobactam 4.5g q 6 hours for 10-14 d

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: adult patients (= 19 years of age) presenting ESBL-E.coli urinary tract infection

Exclusion criteria

Exclusion criteria: presence of suspicious or confirmatory infectious foci other than urinary tract infection, any use of antibiotics within seven days prior to recruitment for any reasons, any complicating urinary factors which could not be effectively treated during trial (obstruction, suspected or confirmed prostatitis, epididymitis), indwelling urinary catheters expected to remain in place after therapy has been completed and need for renal replacement therapy.

Design outcomes

Primary

Measure	Time frame
clinical improvement rate	—

Secondary

Measure	Time frame
Microbiological eradication rate	—

Countries

Korea, Republic of

Contacts

Public ContactYu Bin Seo

Hallym University Medical Center-Kangnam

yubinseo@gmail.com+82-2-829-5531

Outcome results